NF Trinity Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

NF Trinity Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$6.91M	Sell	77,764 -31,000	-29%	-$2.87M	1.1%	24
2018 Q4	$9.26M	Hold	108,764	–	–	1.5%	16
2018 Q3	$10.5M	Hold	108,764	–	–	1.39%	17
2018 Q2	$10.2M	Hold	108,764	–	–	1.4%	16
2018 Q1	$8.82M	Buy	108,764 +18,864	+21%	+$1.62M	1.21%	19
2017 Q4	$8.02M	Hold	89,900	–	–	1.04%	23
2017 Q3	$8.37M	Hold	89,900	–	–	1.19%	22
2017 Q2	$8.16M	Buy	89,900 +34,000	+61%	+$3.09M	1.16%	21
2017 Q1	$4.91M	Buy	+55,900	New	+$4.97M	0.66%	33

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NF Trinity Capital's BMRN Position: Q1 2019 in Review

NF Trinity Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 29% in Q1 2019, selling an estimated $2.87M and leaving 77,764 shares worth $6.91M. The position accounts for 1.1% of the portfolio, ranked #24.

NF Trinity Capital first reported a position in BMRN in Q1 2017 and has held it in 9 quarters since. The position peaked at $10.5M in Q3 2018. 485 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

NF Trinity Capital held 77,764 shares of BioMarin Pharmaceuticals worth $6.91M as of Q1 2019.
NF Trinity Capital sold 31,000 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $2.87M.
BioMarin Pharmaceuticals made up 1.1% of NF Trinity Capital's portfolio in Q1 2019, its #24 holding.
NF Trinity Capital first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 9 quarters since.
NF Trinity Capital's BioMarin Pharmaceuticals position peaked at $10.5M in Q3 2018.
485 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on NF Trinity Capital's 13F filing for Q1 2019, filed 10 May 2019.